Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;38(16):3517-3525.
doi: 10.1007/s11606-023-08364-4. Epub 2023 Aug 24.

Changes in Polypharmacy and Potentially Inappropriate Medications in Homebound Older Adults in Japan, 2015-2019: a Nationwide Study

Shota Hamada  1   2   3 , Masao Iwagami  4 , Nobuo Sakata  4   5 , Yukari Hattori  6 , Kiwami Kidana  7 , Tatsuro Ishizaki  8 , Nanako Tamiya  4 , Masahiro Akishita  6 , Takashi Yamanaka  7
Affiliations

Changes in Polypharmacy and Potentially Inappropriate Medications in Homebound Older Adults in Japan, 2015-2019: a Nationwide Study

Shota Hamada et al. J Gen Intern Med. 2023 Dec.

Abstract

Background: With rising worldwide population aging, the number of homebound individuals with multimorbidity is increasing. Improvement in the quality of home medical care (HMC), including medications, contributes to meeting older adults' preference for "aging in place" and securing healthcare resources.

Objective: To evaluate the changes in drug prescriptions, particularly potentially inappropriate medications (PIMs), among older adults receiving HMC in recent years, during which measures addressing inappropriate polypharmacy were implemented, including the introduction of clinical practice guidelines and medical fees for deprescribing.

Design: A cross-sectional study.

Participants: Using data from the national claims database in Japan, this study included older adults aged ≥ 75 years who received HMC in October 2015 (N = 499,850) and October 2019 (N = 657,051).

Main measures: Number of drugs, prevalence of polypharmacy (≥ 5 regular drugs), major drug categories/classes, and PIMs according to Japanese guidelines were analyzed. Random effects logistic regression models were used to evaluate the differences in medications between 2015 and 2019, considering the correlation within individuals who contributed to the analysis in both years.

Key results: The number of drugs remained unchanged from 2015 to 2019 (median: 6; interquartile range: 4, 9). The prevalence of polypharmacy also remained unchanged at 70.0% in both years (P = 0.93). However, the prescription of some drugs (e.g., direct oral anticoagulants, new types of hypnotics, acetaminophen, proton pump inhibitors, and β-blockers) increased, whereas others (e.g., warfarin, vasodilators, H2 blockers, acetylcholinesterase inhibitors, and benzodiazepines) decreased. Among the frequently prescribed PIMs, benzodiazepines/Z-drugs (25.6% in 2015 to 21.1% in 2019; adjusted odds ratio: 0.52) and H2 blockers (11.2 to 7.3%; 0.45) decreased, whereas diuretics (23.8 to 23.6%; 0.90) and antipsychotics (9.7 to 10.5%; 1.11) remained unchanged.

Conclusions: We observed some favorable changes but identified some continuous and new challenges. This study suggests that continued attention to medication optimization is required to achieve safe and effective HMC.

Keywords: deprescribing; home care; home health care; polypharmacy; potentially inappropriate medications.

PubMed Disclaimer

Conflict of interest statement

SH, KK, and TY belong to an endowed chair funded by donations from Mr. Kazuteru Noguchi, JSH, Towa Pharmaceutical, Sawai Pharmaceutical, and Ain Pharmaciez. SH received research funding from SOMPO Care Inc. outside of this work. NT received research funding from SMS and FAST DOCTOR. MA received remuneration from Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly Japan, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, MSD, Ono Pharmaceutical, Pfizer Japan, Sumitomo Dainippon Pharma, and Takeda Pharmaceutical, and received research funding from Astellas Pharma, AstraZeneca, Bayer Health Care, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kowa Pharmaceutical, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, MSD, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer Japan, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Tsumura. The other authors have no conflicts of interest to declare.

References

    1. Ornstein KA, Garrido MM, Bollens-Lund E, et al. Estimation of the Incident Homebound Population in the US Among Older Medicare Beneficiaries, 2012 to 2018. JAMA Intern Med. 2020;180(7):1022–1025. doi: 10.1001/jamainternmed.2020.1636. - DOI - PMC - PubMed
    1. Lapointe-Shaw L, Jones A, Ivers NM, et al. Homebound Status Among Older Adult Home Care Recipients in Ontario. Canada. J Am Geriatr Soc. 2022;70(2):568–578. doi: 10.1111/jgs.17501. - DOI - PubMed
    1. Qiu WQ, Dean M, Liu T, et al. Physical and Mental Health of Homebound Older Adults: an Overlooked Population. J Am Geriatr Soc. 2010;58(12):2423–2428. doi: 10.1111/j.1532-5415.2010.03161.x. - DOI - PMC - PubMed
    1. Iwata H, Matsushima M, Watanabe T, et al. The Need for Home Care Physicians in Japan – 2020 to 2060. BMC Health Serv Res. 2020;20(1):752. doi: 10.1186/s12913-020-05635-2. - DOI - PMC - PubMed
    1. Arai H, Ouchi Y, Toba K, et al. Japan as the Front-Runner of Super-Aged Societies: Perspectives from Medicine and Medical Care in Japan. Geriatr Gerontol Int. 2015;15(6):673–687. doi: 10.1111/ggi.12450. - DOI - PubMed

Publication types

LinkOut - more resources